Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242942 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
A Phase 3 study of Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
- 20
- Study locations
NCT02242942 is a Phase 3 study of Lymphocytic Leukemia, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 445 participants, above the 55-participant average among 3 other Lymphocytic Leukemia, Chronic trials with a reported enrollment target (709% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02242942, a Phase 3 study of Lymphocytic Leukemia, Chronic, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Chlorambucil
Study Locations (20)
Other
- Hospital Italiano - Buenos Aires
- Tiroler Landeskrankenanstalten Ges.M.B.H. - Innsbruck
- Medizinische Universität Wien - Vienna
Victoria
- Box Hill Hospital - Box Hill
- The Northern Hospital - Epping
- Monash Medical Centre - Melbourne
California
- City of Hope - Duarte
- UC San Diego Health System - La Jolla
New South Wales
- Liverpool Hospital - Liverpool BC
- Tweed Hospital - Tweed Heads
Queensland
- The Townsville Hospital - Douglas
- Princess Alexandra Hospital Woolloongabba - Woolloongabba
South Australia
- Royal Adelaide Hospital - Adelaide
- Ashford Cancer Centre Research - Ashford
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2014-12-31 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02242942
The ClinicalTrials.gov registry entry for NCT02242942 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 3 other Lymphocytic Leukemia, Chronic trials with a reported enrollment target (709% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphocytic Leukemia, Chronic appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT02242942 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Victoria, California.
Frequently Asked Questions
What is clinical trial NCT02242942 about?
NCT02242942 is a clinical study titled "Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia". This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study...
What is the current status of trial NCT02242942?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2014-12-31. Estimated completion is 2025-08-27.
What conditions does trial NCT02242942 study?
This clinical trial studies the following conditions: Lymphocytic Leukemia, Chronic.
What interventions are being tested in trial NCT02242942?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Chlorambucil (DRUG).
Who is sponsoring clinical trial NCT02242942?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02242942 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphocytic Leukemia, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
RECRUITING · Phase 1
-
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
COMPLETED · Phase 1
-
Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.